Preliminary Study the Effect of Galbanic Acid on the Efficacy of Radiation Therapy on O26 Tumor Cells Implanted In Balb-C Mice

Document Type : Original Paper

Authors

1 Department of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Associate Professor of Medical Physics, Research Center of Medical Physics, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Pharmacognosy and Biotechnology, Biotechnology Research Center, Faculty of Pharmacy, Mashhad University of Medical Sciences,Mashhad, Iran

4 - Medical Physics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5 Department of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

6 Faculty of Veterinary Medicine, University of Zabol, Zabol, Iran

7 Zabol University of Medical Sciences, Zabol, Iran

10.22038/ijmp.2023.67023.2156

Abstract

Introduction: In the present study we used Galbanic acid (GA) combined with radiation therapy to raise radiation efficacy. GA extracted from Ferula species and have anti-cancer properties. The purpose of this study is to investigate the effect of Galbanic acid on C26 tumor radiation sensitivity and The main challenge of this study is to deliver the drug to the tumor cells due to the hydrophobicity of Galbanic acid.
Material and Methods: 28 inbred male Balb/C mice were injected subcutaneously with 500,000 C26 cells into the right flank. The mice were divided into 4 groups including group control, radiation alone (R), GA alone (GA), and both radiation and GA (R+GA). Life span, tumor growth and weight of the mice were evaluated. All analyzes were performed by the 26th version of SPSS and P value of less than 0.05.
Results: The median lifespan in group R+GA was 28 days, which was longer than 20 days in group R, 22 days in group GA, and 16 days in the control group. The lifespan of the GA+R group was significantly higher than the other groups (P<0.05). The percentage of growth delay in group R+GA was 78%, while in group R and in group GA it was only 42% and 47%, respectively.
Conclusion: The results showed that the lifespan and tumor growth rate of the mice that received combined treatment was longer and lower, compared to the two groups that received GA or radiation alone.

Keywords

Main Subjects

References

  1. Halperin EC, Brady LW, Wazer DE, Perez CA. Perez & Brady's principles and practice of radiation oncology: Lippincott Williams & Wilkins; 2013.
  2. Manabe Y, Takahashi Y, Sugie C, Wang Z, Katsuki S, Kondo T, et al. Biological effects of prostaglandin E2-EP4 antagonist (AAT-008) in murine colon cancer in vivo: enhancement of immune response to radiotherapy and potential as a radiosensitizer. Translational Cancer Research. 2023;12(2):351.
  3. Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, et al. Antibody-drug conjugates: the new frontier of chemotherapy. International Journal of Molecular Sciences. 2020;21(15):5510.
  4. Dandawate PR, Subramaniam D, Jensen RA, Anant S, editors. Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy. Seminars in cancer biology; 2016: Elsevier.
  5. Liskova A, Kubatka P, Samec M, Zubor P, Mlyncek M, Bielik T, et al. Dietary phytochemicals targeting cancer stem cells. Molecules. 2019;24(5):899.
  6. Chahardoli A, Mavaei M, Shokoohinia Y, Fattahi A. Galbanic acid, a sesquiterpene coumarin as a novel candidate for the biosynthesis of silver nanoparticles: In vitro hemocompatibility, antiproliferative, antibacterial, antioxidant, and anti-inflammatory properties. Advanced Powder Technology. 2023;34(1):103928.
  7. Hanafi-Bojd MY, Iranshahi M, Mosaffa F, Tehrani SO, Kalalinia F, Behravan J. Farnesiferol A from Ferula persica and galbanic acid from Ferula szowitsiana inhibit P-glycoprotein-mediated rhodamine efflux in breast cancer cell lines. Planta medica. 2011;77(14):1590-3.
  8. Kasaian J, Iranshahy M, Iranshahi M. Synthesis, biosynthesis and biological activities of galbanic acid–A review. Pharmaceutical biology. 2014;52(4):524-31.
  9. Nik ME, Malaekeh-Nikouei B, Amin M, Hatamipour M, Teymouri M, Sadeghnia HR, et al. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma. Scientific reports. 2019;9(1):9527.
  10. Eskandani M, Barar J, Ezzati Nazhad Dolatabadi J, Hamishehkar H, Nazemiyeh H. Formulation, characterization, and geno/cytotoxicity studies of galbanic acid-loaded solid lipid nanoparticles. Pharmaceutical biology. 2015;53(10):1525-38.
  11. Afsharzadeh M, Abnous K, Yazdian–Robati R, Ataranzadeh A, Ramezani M, Hashemi M. Formulation and evaluation of anticancer and antiangiogenesis efficiency of PLA–PEG nanoparticles loaded with galbanic acid in C26 colon carcinoma, in vitro and in vivo. Journal of Cellular Physiology. 2019;234(5):6099-107.
  12. Kim YH, Shin EA, Jung JH, Park JE, Koo J, Koo JI, et al. Galbanic acid potentiates TRAIL induced apoptosis in resistant non-small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5. European Journal of Pharmacology. 2019;847:91-6.
  13. Nik ME, Jaafari MR, Mashreghi M, Nikoofal-Sahlabadi S, Amin M, Sadeghnia HR, et al. The effect of RGD-targeted and non-targeted liposomal Galbanic acid on the therapeutic efficacy of pegylated liposomal doxorubicin: From liposomal preparation to in-vivo studies. International journal of pharmaceutics. 2021;604:120710.
  14. Kasaian J, Iranshahy M, Masullo M, Piacente S, Ebrahimi F, Iranshahi M. Sesquiterpene lactones from Ferula oopoda and their cytotoxic properties. Journal of Asian natural products research. 2014;16(3):248-53.
  15. Eskandani M, Abdolalizadeh J, Hamishehkar H, Nazemiyeh H, Barar J. Galbanic acid inhibits HIF-1α expression via EGFR/HIF-1α pathway in cancer cells. Fitoterapia. 2015;101:1-11.
  16. Oh BS, Shin EA, Jung JH, Jung DB, Kim B, Shim BS, et al. Apoptotic effect of galbanic acid via activation of caspases and inhibition of Mcl‐1 in H460 non‐small lung carcinoma cells. Phytotherapy Research. 2015;29(6):844-9.

 

Iranian Journal of Medical Physics
Volume 21, Issue 5 - Serial Number 5
September and October 2024
Pages 323-328

Files

History

  • Receive Date: 30 July 2022
  • Revise Date: 27 September 2024
  • Accept Date: 09 April 2023

Share

How to cite

Statistics